Immunocore Holdings plc (IMCR) stock
IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3014% below fair value
$27.81−1.07 (-3.70%)
Close on Nov 17, 2026Market cap $1.43BP/E –Yield 0.00%
Immunocore total assets
Total assets on the balance sheet at the end of each period.
Immunocore's total assets was $1.12B at Jun 30, 2026. For fiscal 2025 it was $1.07B, up 5.7% from the year before.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.07B | +5.7% |
| FY2024 | Dec 31, 2024 | $1.01B | +69.1% |
| FY2023 | Dec 31, 2023 | $597.00M | +13.3% |
| FY2022 | Dec 31, 2022 | $526.76M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.12B | +3.4% |
| Q1 FY2026 | Mar 31, 2026 | $1.07B | +4.3% |
| Q4 FY2025 | Dec 31, 2025 | $1.07B | +5.7% |
| Q3 FY2025 | Sep 30, 2025 | $1.10B | +1.6% |
| Q2 FY2025 | Jun 30, 2025 | $1.08B | +5.8% |
| Q1 FY2025 | Mar 31, 2025 | $1.03B | +3.4% |
| Q4 FY2024 | Dec 31, 2024 | $1.01B | +69.1% |
| Q3 FY2024 | Sep 30, 2024 | $1.08B | +105.9% |
| Q2 FY2024 | Jun 30, 2024 | $1.02B | – |
| Q1 FY2024 | Mar 31, 2024 | $993.99M | – |
| Q4 FY2023 | Dec 31, 2023 | $597.00M | – |
| Q4 FY2022 | Dec 31, 2022 | $526.76M | – |
See a number that looks wrong?